Findings from University of Pisa Update Understanding of Colon Cancer (Treatment of Patients With Brafv<superscript>600e</superscript>-mutated Metastatic Colorectal Cancer After Progression To Encorafenib and Cetuximab: Data From a Real-world Nationwide Data.

A recent study conducted by researchers at the University of Pisa in Italy examined the treatment of patients with BRAF(V600E)-mutated metastatic colorectal cancer (mCRC) who had received encorafenib and cetuximab therapy. The study found that the median progression-free survival (mPFS) for these patients was approximately 4 months, and little is known about subsequent therapies and their effectiveness. The researchers analyzed a real-world dataset of 179 patients and found that those who received targeted therapy (TT) in the second line were more likely to receive subsequent therapies and had longer postprogression survival (PPS). Among patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors, combinatory chemotherapy +/- anti-vascular endothelial growth factor (anti-VEGF) was associated with longer PFS and PPS compared to other treatments. The study suggests that TT should be initiated as soon as possible after the failure of first-line treatment in BRAF(V600E)-mutated mCRC. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)